FDA issues alert on a drug combination to treat triple-negative breast cancer
Full article:,or%20metastatic%20triple%20negative%20breast

The immunotherapy drug Tecentriq (atezolizumab) is approved for use with Abraxane (nab-paclitaxel) to treat metastatic triple-negative breast cancer. Tecentriq is NOT approved for use with Taxol (paclitaxel). The Food and Drug Administration has issued an alert to doctors, researchers and patients warning that Tecentriq should not be used in combination with Taxol to treat patients with advanced triple-negative breast cancer. (09/18/20)

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies looking at new treatments for people with metastatic TNBC.  

A number of other clinical trials for treating patients with metastatic TNBC can be found here.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.